Clearside Biomedical, Inc. (NASDAQ:CLSD) is set to announce second quarter earning results on Monday 10th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, CLSD to report 2Q20 loss of $ 0.12 per share.
For the full year, analysts anticipate top line of $ 7.81 million, while looking forward to loss of $ 0.44 per share bottom line.
Previous Quarter Performance
Clearside Biomedical, Inc. disclosed loss for the first quarter of $ 0.07 per share, from the revenue of $ 4.10 million. The quarterly earnings fell 60.87 percent compared with the same quarter last year. The consensus estimates are in revenue The bottom line results street analysts by $ 0.02 or , at the same time, top line results analysts by $ 0.14 million or .
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Clearside Biomedical, Inc.
Stock Performance
According to the previous trading day, closing price of CLSD was $ 1.76, representing a 214.29 % increase from the 52 week low of $ 0.56 and a 57.38 % decrease over the 52 week high of $ 4.13.
The company has a market capital of $ 95.59 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CLSD” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Clearside Biomedical, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.clearsidebio.com
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
